T-cell Acute Lymphoblastic Lymphoma
📧 Sign up to get email alerts when something new happens for T-cell Acute Lymphoblastic Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Universal 4SCAR7U Targeting CD7-positive Malignancies [Phase 1]
A Phase 1 trial evaluating Universal 4SCAR7U, a CD7-targeting therapy from Shenzhen Geno-Immune Medical Institute, is currently recruiting. …
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma [Phase 1]
This Phase 1 study investigates a quadruplet regimen of venetoclax, dexamethasone, bortezomib, and daratumumab in adolescents and young adul…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma [Phase 1]
Phase 1 clinical trial evaluating targeted immunotherapy after myeloablative conditioning and allogeneic stem cell transplant in children an…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells [Phase 1]
A Phase 1 clinical trial update on an allogeneic CD7-targeted CAR-T cell therapy for high-risk T-cell malignancies (T-cell acute lymphoblast…
-
CLINICAL_TRIALS research · 2025-10-23Clinical Trial Update: Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells [Phase 1]
A Phase 1 clinical trial evaluates CD7-targeted CAR-T cells derived from autologous T cells for high-risk T-cell malignancies and is current…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-09-04Clinical Trial Update: Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen [Phase 1]
Phase 1 trial evaluating autologous CD5-targeted CAR T cells for T-cell malignancies expressing CD5, currently recruiting.